Related Experiment Video

Updated: May 7, 2026

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.0K

[Prevention of serogroup B meningococcal disease using a four-component vaccine]

A Gil1, D Barranco2, J Batalla3

  • 1Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Madrid, España.

Anales De Pediatria (Barcelona, Spain : 2003)
|October 15, 2013
PubMed
Abstract

Insights

The new 4CMenB vaccine offers a potential strategy against serogroup B meningococcal disease, a predominant infection. Clinical trials confirm its safety and immunogenicity across various age groups.

Area of Science:

  • Vaccinology and Public Health
  • Infectious Disease Prevention
  • Reverse Vaccinology Applications

Context:

  • Meningococcal disease, particularly serogroup B, remains a significant public health concern.
  • Development of effective vaccines against Neisseria meningitidis serogroup B has been challenging.
  • The 4CMenB vaccine represents a novel approach to combatting this infection.

Purpose:

  • To review existing data on the 4CMenB vaccine.
  • To assess its potential contribution to preventing meningococcal infections.
  • To evaluate its safety, immunogenicity, and compatibility with routine vaccinations.

Summary:

  • The 4CMenB vaccine, developed using reverse vaccinology, targets four key meningococcal components.
  • The Meningococcal Antigen Typing System (MATS) indicates broad European strain coverage (70-80%).
  • Clinical trials demonstrate safety and immunogenicity in all age groups, inducing an anamnestic response. Fever incidence is manageable, especially when co-administered with routine vaccines.

Impact:

  • 4CMenB is currently the sole available strategy for preventing serogroup B meningococcal disease.
  • The vaccine is compatible with simultaneous administration with routine infant and child vaccines in Spain.
  • Potential to significantly reduce morbidity associated with Neisseria meningitidis serogroup B.
Keywords:
MeningitisMeningitis meningocócicaMeningococcalMeningococcal vaccinesPrevención y control mesh termsPrevention and control [subheading]VaccinesVacunasVacunas antimeningocócicas

More Related Videos

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

7.0K
Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

4.7K

Related Concept Videos

Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
32
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
49
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
105
Vaccinations01:51

Vaccinations

Overview
44.3K
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
219